TrebananibAMG

TrebananibAMG, also called trebananib or AMG 386, is a peptibody developed by Amgen designed to antagonize the angiopoietin–Tie2 signaling axis in cancer. It binds angiopoietins 1 and 2 with high affinity, preventing their interaction with the Tie2 receptor on endothelial cells and thereby inhibiting angiogenesis in tumors.

In preclinical studies, trebananib demonstrated anti-angiogenic activity and synergistic effects when combined with chemotherapy. It progressed to clinical testing in multiple solid tumors, including ovarian cancer, glioblastoma, colorectal cancer, and other malignancies, typically in combination with standard chemotherapies.

Results from phase II and phase III clinical trials did not show a meaningful improvement in patient outcomes compared with control therapies. In several trials, trebananib failed to meet primary endpoints for overall survival or progression-free survival, leading to the termination of further development for most indications. The pharmacokinetic and safety profiles were generally manageable, but the lack of demonstrated efficacy prevented regulatory approval.

As a result, trebananibAMG is not approved for any cancer indication, and development has largely been discontinued. The experience with trebananib has contributed to the broader understanding of the angiopoietin–Tie2 axis in oncology, illustrating the challenges of translating anti-angiogenic strategies into durable clinical benefits.